Book Review: Biomedical Innovation in Fertility Care – Evidence challenges, commercialisation and the market for hope
By Zeenat Beebeejaun,
PET
| 10. 28. 2024
Building on the 2016 BBC Panorama documentary 'Inside Britain's Fertility Business', which exposed the use of controversial fertility treatment add-ons in private fertility clinics (see BioNews 880), Manuela Perrotta's book, Biomedical Innovation in Fertility Care, unveils regulatory inadequacies that expose patients to abuse by the profit-driven medical industry. Perrotta makes a case for more ethical biomedical innovation in this book and proposes changes that put patients' interests and moral behaviour ahead of business interests.
In doing so, Perrotta explores the commercialisation of reproductive therapies, concentrating on the moral, practical, and legal problems that both experts and patients must deal with. The book criticises the marketing of reproductive treatment add-ons like EmbryoGlue and time-lapse imaging, which are portrayed as potential therapies for supporting pregnancies notwithstanding the lack of solid data proving their efficacy clinics (see BioNews 1240). This system presents serious ethical issues, especially when patients are asked to pay exorbitant costs for experimental procedures.
While reading the book, I found myself reflecting on how Perrotta highlights the restricted role of regulating authorities such as the Competition and...
Related Articles
By Dr. Coco Newton, Progress Educational Trust | 03.30.2026
Have you ever wondered what it means to have dozens of half-siblings across the world – or to never know where half of your genetic identity comes from? A recent episode of Zembla explores the human consequences of the global...
By Marcelo Jauregui-Volpe, Wired | 04.24.2026
Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict.
One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers...
By Alexandre Piquard, Le Monde [cites Katie Hasson] | 04.27.2026
"Si on en prouve la sûreté, nous croyons que l’édition préventive du génome pourrait être l’une des technologies de santé les plus importantes du siècle. » Lucas Harrington explique ainsi le but de son entreprise Preventive : créer des bébés génétiquement modifiés...
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...